ArticleTherapeutic advances in hematology2026
Assessing the value of fibro scan in the detection of liver fibrosis among patients with sickle cell disease- a single center study.
Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sickle cell hepatopathy (SCH) is a general term used to describe the acute and chronic manifestations of liver damage in sickle cell disease (SCD). One of the most effective methods used to examine the liver is transient elastography (Fibro Scan), a noninvasive, rapid, and reproducible method that can assess liver fibrosis by measuring liver stiffness. Objectives: This single-center study aims to investigate the role of transient elastography (Fibro Scan) in the detection of liver disease among patients with SCD in the Eastern Province of Saudi Arabia, where the rates of SCD are found to be among the highest. Design: This is a prospective, observational study. Methods: The study was conducted among n=101 SCD patients of any phenotype between January and December 2024. Data on demographics, hospitalization rates, hydroxyurea use, transfusion, and complications were obtained from the health informatics system. All included patients were examined using non-invasive transient elastography (Fibro Scan) for the presence of fibrotic changes. Results: Among n = 101 SCD patients, 13.9% had G6PD deficiency, 40.6% required one hospitalization per year, and 65.3% required blood transfusion. The transient elastography through Fibro Scan assessments revealed that 94.1% of patients had normal liver tissue (fibrosis score 2-7 kPa), 4.0% showed moderate scarring (7-11 kPa), and 2.0% had moderate to severe scarring (11-15 kPa). Radiographic evidence of fatty liver was present in 24.8% of cases, with a significant association with moderate or severe fibrosis (p = 0.049). Conclusions: Patients with SCD without iron overload had a low prevalence of liver fibrosis. However, fatty liver in SCD likely leads to a risk of fibrosis progression, which is an area for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.